SCHEMBL6079817

SCHEMBL6079817

Cc1cc(NC(=O)NC2CCN(C(Cc3ccccc3)Cc3ccccc3)C2)c2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.50
RAB9A P51151 2/20 0.50
GALR3 O60755 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
UTS2R Q9UKP6 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
ADRA2A P08913 1/20 0.48
DRD2 P14416 1/20 0.48
SLC6A2 P23975 1/20 0.48
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
SLC6A4 P31645 1/20 0.48
TMEM97 Q5BJF2 1/20 0.48
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
IGF1R P08069 2/20 0.44
ALDH1A1 P00352 1/20 0.42
OPRK1 P41145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080227 1.00 HTT (0.50) HTTRAB9AGALR3SMN1; SMN2UTS2R
SCHEMBL6079805 1.00 HTT (0.50) HTTRAB9AGALR3SMN1; SMN2UTS2R
SCHEMBL6079559 0.85 ALDH1A1 (0.50) HTTSMN1; SMN2SIGMAR1DRD2KMT2A
SCHEMBL6079572 0.85 ALDH1A1 (0.50) HTTSMN1; SMN2SIGMAR1DRD2KMT2A
SCHEMBL6080265 0.85 ALDH1A1 (0.50) HTTSMN1; SMN2SIGMAR1DRD2KMT2A
SCHEMBL6078746 0.84 SIGMAR1 (0.59) HTTRAB9AGALR3SMN1; SMN2UTS2R
SCHEMBL6078750 0.84 SIGMAR1 (0.59) HTTRAB9AGALR3SMN1; SMN2UTS2R
SCHEMBL6079692 0.84 SIGMAR1 (0.59) HTTRAB9AGALR3SMN1; SMN2UTS2R
SCHEMBL6079367 0.83 HTT (0.45) HTTRAB9AGALR3SMN1; SMN2UTS2R
SCHEMBL6079689 0.83 HTT (0.45) HTTRAB9AGALR3SMN1; SMN2UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives ACTELION PHARMACEUTICALS LTD (CH) 2006-05-04 US claimed
EP-1554249-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-07-20 EP claimed
WO-2004026836-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-04-01 WO claimed
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives ACTELION PHARMACEUTICALS LTD (CH) 2006-05-04 US disclosed
EP-1554249-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-07-20 EP disclosed
WO-2004026836-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives P2RY4, P2RX4, REN HTT 1465/4885RAB9A 3371/4885GALR3 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.